{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:31:31Z","timestamp":1753893091663,"version":"3.41.2"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Health Serv."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>X-linked hypophosphataemia (XLH) is a rare, genetic, renal phosphate wasting disorder that causes a lifelong rapid progression of morbidities, which are associated with substantial humanistic and economic burden. A structured literature review was carried out to identify publications reporting healthcare resource use and productivity impact of XLH to provide a comprehensive description of the burden.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Literature searches of the Embase\u00ae, Medline\u00ae, and EconLit electronic databases were carried out in August 2022 using free-text and subject heading search terms regarding XLH-related clinical morbidities and associated healthcare resource use, limited to English language records from 1992 onwards.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After screening by pre-specified inclusion\/exclusion criteria, 22 publications were selected for inclusion in the review. Use of conventional pharmacological therapy with oral phosphate and\/or active vitamin D was reported in 15 publications, in up to 100% of paediatric patients and 75% of adults. Findings indicated that a high proportion of patients with XLH undergo orthopaedic procedures\/surgeries, including a history of osteotomy in up to 25% of paediatric patients and 61% of adults, and a history of growth plate stapling in up to 63% of paediatric patients and 20% of adults. A high prevalence of fractures (in up to 61% of adults) and use of assistive mobility devices was also reported. The findings highlighted a substantial prevalence of morbidities, either due to persistently low phosphate levels or complications of conventional therapy, that had directly associated healthcare resource use, including dental problems, hearing problems, hyperparathyroidism, and nephrocalcinosis. Healthcare resource use and associated clinical events were generally found to be higher in adults compared with paediatric patients, which is consistent with the natural history of XLH as a progressive lifelong condition. Studies also highlighted the negative impact of XLH on school attendance and the ability to work.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The results of this structured literature review emphasise the lifelong impact of XLH, showing that it is associated with a substantial economic burden, across many healthcare resource use categories including pharmacological therapy, management of pain and mobility, orthopaedic procedures, morbidities due to XLH or conventional therapy, and work\/school productivity.<\/jats:p><\/jats:sec>","DOI":"10.3389\/frhs.2025.1285246","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:22:47Z","timestamp":1744176167000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A literature review of the healthcare resource use and productivity burden of X-linked hypophosphataemia"],"prefix":"10.3389","volume":"5","author":[{"given":"Rafael","family":"Pinedo-Villanueva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad K.","family":"Javaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Whittle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matilde","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","article-title":"A clinician\u2019s guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter","year":"2011","journal-title":"J Bone Miner Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13023-021-02156-x","article-title":"Potential influences on optimizing long-term musculoskeletal health in children and adolescents with X-linked hypophosphatemia (XLH)","volume":"17","author":"Glorieux","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00424-018-2231-z","article-title":"Physiological regulation of phosphate by vitamin D, parathyroid hormone (PTH) and phosphate (Pi)","volume":"471","author":"Jacquillet","year":"2019","journal-title":"Pfl\u00fcgers Arch"},{"key":"B4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00431-007-0662-1","article-title":"What\u2019s new in hypophosphataemic rickets?","volume":"167","author":"Pettifor","year":"2008","journal-title":"Eur J Pediatr"},{"key":"B5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1530\/EJE-08-0818","article-title":"Incidence and prevalence of nutritional and hereditary rickets in southern Denmark","volume":"160","author":"Beck-Nielsen","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1530\/EJE-15-0515","article-title":"Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications","volume":"174","author":"Rafaelsen","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e871","DOI":"10.1210\/clinem\/dgz203","article-title":"Prevalence and mortality of individuals with X-linked hypophosphatemia: a United Kingdom real-world data analysis","volume":"105","author":"Hawley","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/jhg.2012.56","article-title":"Mutational analysis of PHEX, FGF23, DMP1, SLC34A3 and CLCN5 in patients with hypophosphatemic rickets","volume":"57","author":"Beck-Nielsen","year":"2012","journal-title":"J Hum Genet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00439-009-0631-z","article-title":"PHEX analysis in 118 pedigrees reveals new genetic clues in hypophosphatemic rickets","volume":"125","author":"Gaucher","year":"2009","journal-title":"Hum Genet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1210\/jcem.81.11.8923863","article-title":"X-linked hypophosphatemia: a search for gender, race, anticipation, or parent of origin effects on disease expression in children","volume":"81","author":"Whyte","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1530\/EC-13-0103","article-title":"Therapeutic management of hypophosphatemic rickets from infancy to adulthood","volume":"3","author":"Linglart","year":"2014","journal-title":"Endocr Connect"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1210\/js.2018-00365","article-title":"The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey","volume":"3","author":"Skrinar","year":"2019","journal-title":"J Endocr Soc"},{"key":"B13","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s10545-018-0147-6","article-title":"Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations","volume":"41","author":"Chesher","year":"2018","journal-title":"J Inherit Metab Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e1249","DOI":"10.1210\/clinem\/dgab739","article-title":"Musculoskeletal features in adults with X linked hypophosphatemia: an analysis of clinical trial and survey data","volume":"107","author":"Javaid","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1507\/endocrj.EJ21-0386","article-title":"Burden of disease of X-linked hypophosphatemia in Japanese and Korean patients: a cross-sectional survey","volume":"69","author":"Ito","year":"2022","journal-title":"Endocr J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/jbmr.4206","article-title":"A qualitative thematic analysis of the burden of illness of x-linked hypophosphatemia across the life course. P-768, presented at: 2020 annual meeting of the American society for bone and mineral research. Virtual event, September 11\u201315, 2020","volume":"35","author":"Bubbear","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"bvab070","DOI":"10.1210\/jendso\/bvab070","article-title":"Patient-reported complications, symptoms, and experiences of living with X-linked hypophosphatemia across the life-course","volume":"5","author":"Cheung","year":"2021","journal-title":"J Endocr Soc"},{"key":"B19","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41574-022-00662-x","article-title":"Interdisciplinary management of FGF23-related phosphate wasting syndromes: a consensus statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia","volume":"18","author":"Trombetti","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40265-018-0905-7","article-title":"Burosumab: first global approval","volume":"78","author":"Lamb","year":"2018","journal-title":"Drugs"},{"volume-title":"Highlights of Prescribing Information\u2014Crysvita\u00ae (Burosumab-TWZA) Injection, for Subcutaneous Use","year":"2018","key":"B21"},{"volume-title":"Crysvita: EPAR\u2014Medicine Overview","year":"2021","key":"B22"},{"volume-title":"Regulatory Decision Summary\u2014Crysvita","year":"2018","key":"B23"},{"year":"2019","key":"B24","article-title":"Report on the Deliberation Results"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00467-002-1044-6","article-title":"Hypertension in hypophosphatemic rickets\u2014role of secondary hyperparathyroidism","volume":"18","author":"Alon","year":"2003","journal-title":"Pediatr Nephrol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1515\/jpem-2021-0217","article-title":"Management of patients with X-linked hypophosphatemic rickets during COVID-19 pandemic lockdown","volume":"34","author":"Baroncelli","year":"2021","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B28","first-page":"33","article-title":"Clinical course of hypophosphatemic rickets in 23 adults","volume":"45","author":"Berndt","year":"1996","journal-title":"Clin Nephrol"},{"key":"B29","first-page":"26","article-title":"Clinical aspects of X-linked hypophosphatemic rickets","volume":"43","author":"Chung","year":"2002","journal-title":"Acta Paediatr Taiwan"},{"key":"B30","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.bone.2019.06.025","article-title":"Hyperparathyroidism and parathyroidectomy in X-linked hypophosphatemia patients","volume":"127","author":"DeLacey","year":"2019","journal-title":"Bone"},{"key":"B31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s11832-008-0118-9","article-title":"Metabolic and orthopedic management of X-linked vitamin D-resistant hypophosphatemic rickets","volume":"2","author":"Fucentese","year":"2008","journal-title":"J Child Orthop"},{"key":"B32","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1530\/EC-17-0154","article-title":"Outcomes of orthopedic surgery in a cohort of 49 patients with X-linked hypophosphatemic rickets (XLHR)","volume":"6","author":"Gizard","year":"2017","journal-title":"Endocr Connect"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e224","DOI":"10.1210\/clinem\/dgab580","article-title":"Prevalence of enthesopathies in adults with X-linked hypophosphatemia: analysis of risk factors","volume":"107","author":"Herrou","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1302\/1863-2548.11.170003","article-title":"The orthopaedic management of lower limb deformity in hypophosphataemic rickets","volume":"11","author":"Horn","year":"2017","journal-title":"J Child Orthop"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1007\/s00198-021-05875-w","article-title":"Clinical and molecular characterization of Chilean patients with X-linked hypophosphatemia","volume":"32","author":"Jim\u00e9nez","year":"2021","journal-title":"Osteoporos Int"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/jbmr.3992","article-title":"Hyperparathyroidism in patients with X-linked hypophosphatemia","volume":"35","author":"Lecoq","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"796","DOI":"10.20945\/2359-3997000000296","article-title":"Prevalence and clinical characteristics of X-linked hypophosphatemia in Paran\u00e1, southern Brazil","volume":"64","author":"Moreira","year":"2021","journal-title":"Arch Endocrinol Metab"},{"key":"B38","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13023-021-01729-0","article-title":"Phenotypic characterization of X-linked hypophosphatemia in pediatric Spanish population","volume":"16","author":"Rodr\u00edguez-Rubio","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"B39","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/01241398-199901000-00024","article-title":"The effect of osteotomy on bowing and height in children with X-linked hypophosphatemia","volume":"19","author":"Rohmiller","year":"1999","journal-title":"J Pediatr Orthop"},{"key":"B40","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/jbmr.3614","article-title":"High incidence of cranial synostosis and chiari I malformation in children with X linked hypophosphatemic rickets (XLHR)","volume":"34","author":"Rothenbuhler","year":"2019","journal-title":"J Bone Miner Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e1941","DOI":"10.1002\/mgg3.1941","article-title":"X linked hypophosphatemic rickets: description of seven new variants in patients followed up in reference hospitals in Rio de Janeiro","volume":"10","author":"Sant\u2019 Ana","year":"2022","journal-title":"Mol Genet Genomic Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.jval.2018.01.013","article-title":"Qualitative research to explore the patient experience of X-linked hypophosphatemia and evaluate the suitability of the BPI-SF and WOMAC\u00ae as clinical trial end points","volume":"21","author":"Theodore-Oklota","year":"2018","journal-title":"Value Health"},{"key":"B43","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/s0002-9343(97)90023-1","article-title":"The socioeconomic burden of fractures: today and in the 21st century","volume":"103","author":"Johnell","year":"1997","journal-title":"Am J Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"807","DOI":"10.2106\/JBJS.N.00925","article-title":"The cost-effectiveness of surgical treatment of medial unicompartmental knee osteoarthritis in younger patients: a computer model-based evaluation","volume":"97","author":"Konopka","year":"2015","journal-title":"J Bone Joint Surg Am"},{"article-title":"National cost collection for the NHS","volume-title":"Costing in the NHS","year":"2021","key":"B45"},{"key":"B46","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1515\/jpem-2021-0775","article-title":"Complications of orthopedic treatment in patients diagnosed with X-linked hypophosphatemic rickets","volume":"35","author":"Paludan","year":"2022","journal-title":"J Pediatr Endocrinol Metab"},{"volume-title":"Burosumab for Treating X Linked Hypophosphataemia in Children and Young People","year":"2018","key":"B47"},{"key":"B48","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00198-020-05548-0","article-title":"Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review","volume":"32","author":"Seefried","year":"2021","journal-title":"Osteoporos Int"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e10672","DOI":"10.1002\/jbm4.10672","article-title":"Burosumab and dental abscesses in children with X-linked hypophosphatemia","volume":"6","author":"Gadion","year":"2022","journal-title":"JBMR Plus"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e002676","DOI":"10.1136\/rmdopen-2022-002676","article-title":"The benefit of burosumab in adults with X-linked hypophosphatemia (XLH) is maintained with long-term treatment","volume":"9","author":"Kamenick\u00fd","year":"2023","journal-title":"RMD Open"},{"volume-title":"Crysvita Summary of Product Characteristics","year":"","key":"B52"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1211426","DOI":"10.3389\/fendo.2023.1211426","article-title":"Anticipated effects of burosumab treatment on long-term clinical sequelae in XLH: expert perspectives","volume":"14","author":"Seefried","year":"2023","journal-title":"Front Endocrinol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1007\/s12325-019-01193-0","article-title":"Exploring the burden of X-linked hypophosphataemia: an opportunistic qualitative study of patient statements generated during a technology appraisal","volume":"37","author":"Ferizovi\u0107","year":"2020","journal-title":"Adv Ther"}],"container-title":["Frontiers in Health Services"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frhs.2025.1285246\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:22:51Z","timestamp":1744176171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frhs.2025.1285246\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":54,"alternative-id":["10.3389\/frhs.2025.1285246"],"URL":"https:\/\/doi.org\/10.3389\/frhs.2025.1285246","relation":{},"ISSN":["2813-0146"],"issn-type":[{"type":"electronic","value":"2813-0146"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"article-number":"1285246"}}